This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Recent Price Trend in Terumo (TRUMY) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Terumo (TRUMY) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in Terumo (TRUMY) Should Keep going
by Zacks Equity Research
Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Are You Looking for a Top Momentum Pick? Why Terumo Corp. (TRUMY) is a Great Choice
by Zacks Equity Research
Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Terumo (TRUMY) a New Buy Stock
by Zacks Equity Research
Terumo (TRUMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
by Zacks Equity Research
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for March 28th
by Zacks Equity Research
TRUMY, CIFR and STR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 28, 2023.
New Strong Buy Stocks for March 28th
by Zacks Equity Research
XRX, REYN, TRUMY, DQ and STR have been added to the Zacks Rank #1 (Strong Buy) List on March 28, 2023.
Here's What Could Help Terumo Corp. (TRUMY) Maintain Its Recent Price Strength
by Zacks Equity Research
Terumo Corp. (TRUMY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Terumo Corp. (TRUMY) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Terumo Corp. (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Terumo Corp. (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Terumo Corp. (TRUMY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Recent Price Trend in Terumo Corp. (TRUMY) is Your Friend, Here's Why
by Zacks Equity Research
Terumo Corp. (TRUMY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space
by Zacks Equity Research
Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.
Terumo's (TRUMY) MicroVention Enters Transradial Access Space
by Zacks Equity Research
The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.
Boston Scientific (BSX) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Boston Scientific (BSX) shares rose more than 7% in the last trading session, amid huge volumes.
ICU Medical (ICUI) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
ICU Medical (ICUI) saw its shares rise over 10% on the day.
Haemonetics (HAE) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.
Stryker (SYK) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Stryker Corporation (SYK) saw its shares rise over 7% on the day after the company reported better-than-expected third-quarter results.
NuVasive (NUVA) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
NuVasive, Inc. (NUVA) saw its shares rise over 8% on the day after the company reported better-than-expected third-quarter results and announced a major stock repurchase program.
MedTech Growing on Emerging Markets, M&A: Stocks to Buy
by Zacks Equity Research
Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.